Period31 Jul 2024

Media coverage

1

Media coverage

  • TitleCastleVax Inc. Receives $34 Million from BARDA to Continue Advancing Intranasal NDV-based COVID-19 Vaccine into Phase 2b Clinical Efficacy Testing
    Media name/outletImpact Financial News
    Country/TerritoryUnited Kingdom
    Date31/07/24
    PersonsFlorian Krammer, Peter Palese, Adolfo Garcia-Sastre, Weina Sun